AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

AstraZeneca’s (AZN) first-quarter 2024 core earnings of $1.03 per American depositary share (ADS) beat the Zacks Consensus Estimate of 95 cents. Core earnings of $2.06 per share rose 7% year over year on a reported basis and 13% at constant exchange rates (“CER”).Total revenues of $12.68 billion rose 17% on a reported basis and 19% at CER, driven by rising product sales and continued growth in Alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $11.92 billion.All g ...